Research programme: antibacterials - Debiopharm

Drug Profile

Research programme: antibacterials - Debiopharm

Alternative Names: Biodefense therapeutics - Debiopharm; FabI inhibitors - Debiopharm; Oral tularemia therapeutic - Debiopharm

Latest Information Update: 20 Feb 2014

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Affinium Pharmaceuticals
  • Developer Debiopharm Group
  • Class Small molecules
  • Mechanism of Action Enoyl-ACP reductase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Preclinical Bacterial infections; Tularaemia

Most Recent Events

  • 11 Feb 2014 Debiopharm Group acquires Affinium Pharmaceuticals
  • 03 Oct 2007 Data presented at the 47th Interscience Conference on Antimicrobial Agents and Chemotherapeutics (ICAAC-2007) added to the Antimicrobial Acitvity and Bacterial Infections pharmacodynamics sections ,
  • 28 Mar 2007 Affinium Pharmaceuticals closes $US18 million in Series A financing
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top